Publications

Filter Publications By:

Filanesib / Multiple Myeloma

04/04/2013

International Myeloma Workshop

Single-Agent Activity of the Novel KSP Inhibitor ARRY-520 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from Subgroup Analyses

S. Lonial, M.D. et al.

Filanesib / Multiple Myeloma

04/04/2013

International Myeloma Workshop

A Phase 1 Study of ARRY-520 with Bortezomib in Relapsed or Refractory Multiple Myeloma

A. Chari, M.D., et al.

Binimetinib / Cancer

02/13/2013

The Lancet Oncology

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

P. A. Ascierto, et al.

Selumetinib / Cancer

12/21/2012

The Lancet Oncology

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

J. Farley, et al.

Filanesib / Multiple Myeloma

12/10/2012

American Society of Hematology Annual Meeting

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

J.J. Shah, MD, et al.

Filanesib / Multiple Myeloma

12/10/2012

American Society of Hematology Annual Meeting

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

J.J. Shah, MD, et al.

ARRY-614 / MDS

12/09/2012

American Society of Hematology Annual Meeting

Role of p38 MAPK and Tie2 in the Pathogenesis of MDS and Their Inhibition by Dual Inhibitor ARRY-614

S. L. Winski, et al.

Filanesib / Multiple Myeloma

12/08/2012

American Society of Hematology Annual Meeting

Identification of Alpha 1-Acid Glycoprotein (AAG) as a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM)

B.J. Tunquist, et al.

Selumetinib / Cancer

11/28/2012

The Lancet Oncology

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

P. A. Janne, et al.

ARRY-380 / Breast Cancer

10/17/2012

American Association of Pharmaceutical Scientists, Annual Meeting and Exposition

Amorphous Dispersion Development of ARRY-380, an ErbB2 Selective Inhibitor

C. Lindemann, et al.